Switch studies in virologically suppressed patients

Switch to ATV/r monotherapy
ATARITMO
Original article : AIDS. 2007 Jun 19;21(10):1309-15 – P Vernazza

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Limited pilot study, no control arm
  • Caution: risk of compartmentalisation of HIV RNA replication in the CSF

Design :


Primary endpoint :

  • Confirmed virologic failure by W24 (2 consecutive HIV-1 RNA > 400 c/mL, or 3 consecutive HIV-1 RNA > 200 c/mL, or 4 consecutive HIV-1 RNA > 100 c/mL)

Other endpoints

  • Prior ARV therapy
  • Mean CD4 cell count at inclusion = 618/mm3

  • 2 virologic failures (7%)
  • Among 20 patients with plasma HIV-RNA < 50 c/mL at W24, CSF HIV-1 RNA was > 100 c/mL in 3

 

Back to Table of Contents

     
     
     
Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei